The universe of arachidonic acid metabolites in inflammatory bowel disease: can we tell the good from the bad?

@article{Stenson2014TheUO,
  title={The universe of arachidonic acid metabolites in inflammatory bowel disease: can we tell the good from the bad?},
  author={William F. Stenson},
  journal={Current Opinion in Gastroenterology},
  year={2014},
  volume={30},
  pages={347–351}
}
  • W. Stenson
  • Published 1 July 2014
  • Medicine
  • Current Opinion in Gastroenterology
Purpose of review This review summarizes recent developments in the role of soluble mediators of inflammation, particularly arachidonic acid metabolites, in inflammatory bowel disease (IBD). Recent findings The role of prostaglandin E2 in immune regulation has been better defined. Prostaglandin E2 promotes not only immune tolerance and epithelial homeostasis but also the proinflammatory Th17 pathway. Prostaglandin D2 has been established as promoting the resolution of inflammation in the… 
Emerging roles of metabolites of ω3 and ω6 essential fatty acids in the control of intestinal inflammation
TLDR
The recent discovery of novel dietary ω3 and ω6 lipid-derived metabolites and their potent biologic effects on the regulation of inflammation have initiated a new era of nutritional immunology.
Coumarin Derivatives in Inflammatory Bowel Disease
TLDR
This review described the main coumarin derivatives reported as intestinal anti-inflammatory products and its available pharmacodynamic data that support the protective effects of these products in the acute and subchronic phase of intestinal inflammation.
Arachidonic Acid Metabolism and Kidney Inflammation
TLDR
Observations support an extraordinary interest in a wide range of studies on drug interventions aiming to control AA metabolism and kidney inflammation.
Inflammatory Pathways and In Vivo Studies of Inflammatory Bowel Disease
TLDR
The complexity and development of IBD onset is intermediated by a variety of inflammatory mediators and pathways that are intrinsically linked and are summarized in this chapter.
Polyunsaturated Fatty Acids and Their Derivatives: Therapeutic Value for Inflammatory, Functional Gastrointestinal Disorders, and Colorectal Cancer
TLDR
A growing body of evidence suggesting the usefulness of PUFAs in active therapy of various gastrointestinal diseases and their possible use in inflammatory bowel disease, functional gastrointestinal disorders, and colorectal cancer is suggested.
Dietary Fatty Acids and Other Nutrients in Relation to Inflammation and Particularly to Oral Mucosa Inflammation. A Literature Review
TLDR
It is hypothesize that n-3 FAs reduce the oral mucosa inflammation thus decreasing the risk of developing precancerous lesions and cancer, and should be carried out as a contribution to the oral cancer prevention.
Inhibition of 5-Lipoxygenase Derived Leukotrienes and Hemiketals as a Novel Anti-Inflammatory Mechanism of Urolithins.
TLDR
The results show that physiologically relevant colonic urolithins target eicosanoid biosynthetic pathways and the effect on HKs and LTB4 formation is unprecedented and expands the knowledge on anti-inflammatory mechanisms of urologyithins against IBDs.
COX-2–PGE2 Signaling Impairs Intestinal Epithelial Regeneration and Associates with TNF Inhibitor Responsiveness in Ulcerative Colitis
TLDR
It is demonstrated that COX-2–PGE2 signaling has dual functions during tissue repair and normal lineage differentiation, explaining in part the lack of response to TNF inhibitors among PNRs.
Sphingolipids and Epoxidized Lipid Metabolites in the Control of Gut Immunosurveillance and Allergy
TLDR
The effects and functions of lipids, especially sphingolipids and new lipid metabolites originated from dietary oil on the immunomodulation and on the development and pathogenesis of allergic diseases in the intestine are described.
Lactobacillus rhamnosus GG increases cyclooxygenase‐2 expression and prostaglandin E2 secretion in colonic myofibroblasts via a MyD88‐dependent mechanism during homeostasis
TLDR
The data suggest that LbGG increases release of COX‐2‐mediated PGE2, contributing to the maintenance of mucosal homeostasis in the colon and CMFs are among the major contributors to this process.
...
1
2
3
...

References

SHOWING 1-10 OF 41 REFERENCES
A pro-resolution mediator, prostaglandin D2, is specifically up-regulated in individuals in long-term remission from ulcerative colitis
TLDR
Results show a marked up-regulation of synthesis of an antiinflammatory prostanoid and expression of its receptor, specifically in individuals in long-term remission from UC, consistent with animal studies showing the importance of PGD2 in the induction and maintenance of remission from colitis.
Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.
TLDR
The presence of significant amounts of leukotriene B4 in colonic mucosa in patients with inflammatory bowel disease, combined with the known biologic effects of leucotrienes B4, suggests that it may be an important mediator of inflammation in inflammatory bowel Disease.
Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis.
TLDR
The presence of L-PGDS in the COX-2-expressing cells in the mucosa of active UC patients is reported for the first time and an animal model study suggests that PGD(2) derived from L- PGDS- expressing cells plays proinflammatory roles in colitis.
The Proinflammatory Effect of Prostaglandin E2 in Experimental Inflammatory Bowel Disease Is Mediated through the IL-23→IL-17 Axis1
TLDR
It is proposed that high levels of PGE2 exacerbate the inflammatory process in inflammatory bowel disease through the preferential expression and release of DC-derived IL-23 and the subsequent support of the autoreactive/inflammatory Th17 phenotype.
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis.
TLDR
It is demonstrated that induction of colitis results in a rapid increase in prostaglandin D(2) synthesis via cyclooxygenase-2, which downregulates granulocyte infiltration into the colonic mucosa, probably through the DP receptor.
Eicosanoids and the gastrointestinal tract.
TLDR
A large body of work pertaining to studies of eicosanoids in the gastrointestinal tract is distill to present a clear summary of this area of gastroenterology so that future research can be directed in a logical and productive manner.
Induction of epithelial arachidonate 12-lipoxygenase at active sites of inflammatory bowel disease.
TLDR
The increased levels of 12-lipoxygenase antigen in the mucosal and glandular epithelial cells in regions of colon affected by inflammatory bowel disease, the corresponding increases in 12- Lip Oxygenase activity, and the absence of detectable 12- lipoxygen enzyme antigen or enzymatic activity in the same cell types in noninflamed colonic tissue all suggest that epithelial cell 12-ipoxygenases is induced by local mediators of colonic inflammation.
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction
TLDR
These studies demonstrate an important role for COX-2, possibly via generation of PGD2, in mediating the prolonged epithelial secretory and barrier dysfunction after a bout of colitis in the rat.
Selective COX‐2 inhibitors and human inflammatory bowel disease
TLDR
These prostanoids, particularly PGE2 and PGI2, may well be protective as inflammatory bowel disease is aggravated by NSAID use.
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2.
Cyclooxygenase type 1 is constitutively expressed and accounts for synthesis of prostaglandins in the normal gastrointestinal tract. Cyclooxygenase-2 is expressed at sites of inflammation. Selective
...
1
2
3
4
5
...